Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

CD20 Protein-VLP (AA 1-297)

MS4A1 Spezies: Human Wirt: HEK-293 Cells VLP > 95 % as determined by HPLC Imm, ELISA, Func, SPR Active
Produktnummer ABIN7448156
  • Target Alle CD20 (MS4A1) Proteine anzeigen
    CD20 (MS4A1) (Membrane-Spanning 4-Domains, Subfamily A, Member 1 (MS4A1))
    Protein-Typ
    VLP
    Biologische Aktivität
    Active
    Proteineigenschaft
    AA 1-297
    Spezies
    • 22
    • 3
    • 1
    • 1
    Human
    Quelle
    • 11
    • 8
    • 3
    • 2
    • 1
    • 1
    • 1
    HEK-293 Cells
    Applikation
    Immunogen (Imm), ELISA, Functional Studies (Func), Surface Plasmon Resonance (SPR)
    Verwendungszweck
    Human CD20 Protein-VLP
    Sequenz
    Met1-Pro297
    Produktmerkmale
    Recombinant Human CD20 Protein-VLP is expressed from HEK293.It contains Met1-Pro297.
    Reinheit
    > 95 % as determined by HPLC
    Sterilität
    0.22 μm filtered
    Endotoxin-Niveau
    Less than 1EU per μg by the LAL method.
    Biological Activity Comment
    Immobilized Human CD20 VLP at 5μg/ml (100μl/Well) on plate on the plate. Dose response curve for Rituximab, hFc Tag with the EC50 of 8.7ng/ml determined by ELISA (QC Test).
    Top Product
    Discover our top product MS4A1 Protein
  • Applikationshinweise
    • Antibody Discovery: Immunization, Screening, Functional Characterization
    • Affinity determination: ELISA, SPR
    • In vivo pharmacokinetic analysis
    • CMC method development
    • CAR-T Positive Rate Detection
    • Blood sample determination: ELISA
    Kommentare

    Virus-like particles (VLPs) are formed from the outer capsid protein of a virus and are tiny nanoparticles formed by the automatic assembly of one or more capsid proteins. VLPs do not contain viral infectious genomes, so they are relatively safe during production operations. The SAMS™ protein engineering platform has been used to express a series of biotinylated, non-biotinylated, and fluorescently-labeled VLP-displayed antigens. They are suitable for SPR, ELISA, CAR-T positive rate detection, and other experimental scenarios.

    Virus-Like Particles (VLPs) are highly immunogenic, meaning that they can elicit a strong immune response in the host. VLPs are recognized by the immune system and are taken up by antigen-presenting cells (APCs) such as dendritic cells. Once taken up by APCs, VLPs are processed and presented to T cells, which can trigger the activation of B cells to produce antibodies against the displayed antigen. Because VLPs resemble the structure and composition of native viruses, they are highly effective at inducing both humoral and cellular immune responses.

    Generally, VLPs range in size from approximately 20 to 200 nanometers (nm). Compared to a cell-based immunization approach, their smaller size can optimize the immune response to target the specific antigen displayed on the surface of the engineered VLPs.

    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Buffer
    Supplied as 0.22μm filtered solution in PBS ( pH 7.4). Notice: If you need it for immunization, Do Not use any adjuvant.
    Lagerung
    -80 °C
    Informationen zur Lagerung
    Valid for 12 months from date of receipt when stored at -80°C., Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
    Haltbarkeit
    12 months
  • Target
    CD20 (MS4A1) (Membrane-Spanning 4-Domains, Subfamily A, Member 1 (MS4A1))
    Andere Bezeichnung
    CD20 (MS4A1 Produkte)
    Synonyme
    B1 Protein, Bp35 Protein, CD20 Protein, CVID5 Protein, LEU-16 Protein, MS4A2 Protein, S7 Protein, AA960661 Protein, Cd20 Protein, Ly-44 Protein, Ms4a2 Protein, MS4A1 Protein, bp35 Protein, cd20 Protein, ms4a2 Protein, leu-16 Protein, ms4a4c Protein, cd20-like Protein, membrane spanning 4-domains A1 Protein, membrane-spanning 4-domains, subfamily A, member 1 Protein, B-lymphocyte antigen CD20 Protein, MS4A1 Protein, Ms4a1 Protein, ms4a1 Protein, LOC101694281 Protein
    Hintergrund
    B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.
    Molekulargewicht
    34.3 kDa.
Sie sind hier: